Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

ELISA or ELISPOT Detection: The biotinylated MAb11 antibody is useful as the detection antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the purified MAb1 antibody (Cat. No. 502802/502804) as the capture antibody.

Flow Cytometry^3,5,6,10: The fluorochrome-labeled MAb11 antibody is useful for intracellular and membrane-bound immunofluorescent staining and flow cytometric analysis to identify TNF-a-producing cells within mixed cell populations.

Additional reported applications (for the relevant formats) include: neutralization^1,2, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections⁴ and acetone-fixed frozen tissue sections⁸, immunocytochemistry⁷, and immunofluorescence⁹. The MAb11 antibody can neutralize the bioactivity of natural or recombinant TNF-a.

Note: For testing human TNF-a in serum or plasma, BioLegend's ELISA Max? Sets (Cat. No. 430201 to 430206) are specially developed and recommended. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of human TNF-a bioactivity (Cat. No. 502922).

The Purified MAb1 antibody is useful in neutralization² and as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated MAb11 antibody (Cat. No. 502904/502914) as the detecting antibody.

Clone MAb11 cross-reacts to Cat¹¹

1. Rathjen D, et al. 1991. Mol. Immunol. 28:79. (Neut)
2. Ablamunits V, et al. 2010. Eur. J. Immunol. 40:2891. (Neut)
3. Enr quez J, et al. 2002. Adv. Perit. Dial. 18:177. (ICFC)
4. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
5. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
6. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
7. Andersson U, et al. 2000. J. Exp. Med. 192:565. (ICC)
8. Moormann AM, et al. 1999. J. Infect. Dis. 180:1987. (IHC)
9. Zhao XJ, et al. 2003. J. Immunol. 170:2923. (IF)
10. Rieger R, et al. 2009. Cancer Gene Ther. 1:53-64. (FC)
11. Maksaereekul S, et al. 2009. Vaccine. 28:3754 (FC)

1. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
2. Wang Y, et al. 2014. Sci Rep. 4:5346. PubMed
3. Crostarosa F, et al. 2009. PLoS One. 4:e8060. PubMed
4. Nesterenko PA, et al. 2021. Cell Rep. 37:110167. PubMed
5. Hong S, et al. 2015. Brain Behav Immun. Available online 20 August 2015. PubMed
6. Lamichhane R, et al. 2020. Eur J Immunol. 50:178. PubMed
7. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
8. Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed
9. Petrelli A, et al. 2018. J Clin Invest. 128:4669. PubMed
10. Wu HL, et al. 2018. J Immunol. 200:49. PubMed
11. Gleason M, et al. 2014. Blood. 123:3016. PubMed
12. Luo Y, et al. 2021. Front Immunol. 12:761209. PubMed
13. Vagenas P, et al. 2010. PLoS One. 5:e12891. PubMed
14. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
15. Om K, et al. 2020. PLoS Pathog. 16:e1008764. PubMed
16. Cruz–Zárate D, et al. 2018. J Immunol. 201:3401. PubMed
17. Sugita S, et al. 2013. J Immunol. 190:5799. PubMed
18. Dai Z, et al. 2009. J Exp Med. 206:793. PubMed
19. Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed
20. Nesterenko PA, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
21. Lamichhane R et al. 2019. Cell Rep. 28(12):3061-3076 . PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. Beutler B, et al. 1988. Annu. Rev. Biochem. 57:505.
3. Beutler B, et al. 1989. Annu. Rev. Immunol. 7:625.
4. Tracey K, et al. 1993. Crit. Care Med. 21:S415.